1. Barrett NR. Chronic peptic ulcer of the oesophagus and 'oesophagitis'. Br J Surg 1950;38:175–182.
2. Barrett NR. The lower esophagus lined by columnar epithelium. Surgery 1957;41:881–894.
3. Pickens A, Orringer MB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg 2003;76:S1367–S1369.
4. Edgren G, Adami HO, Weiderpass E, Nyrén O. A global assessment of the oesophageal adenocarcinoma epidemic. Gut 2013;62:1406–1414.
6. Coleman HG, Xie SH, Lagergren J. The epidemiology of esophageal adenocarcinoma. Gastroenterology 2018;154:390–405.
9. Choi CY, Suh S, Park JS, et al. The prevalence of Barrett's esophagus and the comparison of Barrett's esophagus with cardiac intestinal metaplasia in the health screening at a secondary care hospital. Korean J Gastroenterol 2012;60:219–223.
10. Lee JH. Barrett's esophagus - with emphasis on endoscopic disgnosis. Korean J Gastrointest Endosc 2009;39:185–198.
12. Tileston W. Peptic ulcer of the oesophagus. Am J Med Sci 1906;132:240.
13. Allison PR. Peptic ulcer of the esophagus. J Thorac Surg 1946;15:308–317.
16. Adler RH. The lower esophagus lined by columnar epithelium. Its association with hiatal hernia, ulcer, stricture, and tumor. J Thorac Cardiovasc Surg 1963;45:13–34.
17. Bani-Hani KE, Bani-Hani BK. Columnar-lined esophagus: time to drop the eponym of "Barrett": historical review. J Gastroenterol Hepatol 2008;23:707–715.
19. Bani-Hani KE, Bani-Hani BK. Columnar lined (Barrett's) esophagus: future perspectives. J Gastroenterol Hepatol 2008;23:178–191.
20. Carrie A. Adenocarcinoma of the upper end of the oesophagus arising from ectopic gastric epithelium. Br J Surg 1950;37:474.
22. Thomas JV, Hay LJ. Adenocarcinoma of the esophagus; report of a case of glandular metaplasia of the esophageal mucosa. Surgery 1954;35:635–639.
24. Puestow CB, Gillesby WJ, Guynn VL. Cancer of the esophagus. AMA Arch Surg 1955;70:662–671.
25. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212–215.
26. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999;94:2037–2042.
27. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994;344:1533–1536.
29. Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett's esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement. Endoscopy 2017;49:191–198.
30. Chandrasoma P, Wijetunge S, DeMeester S, et al. Columnar-lined esophagus without intestinal metaplasia has no proven risk of adenocarcinoma. Am J Surg Pathol 2012;36:1–7.
31. Murphy SJ, Johnston BT, Murray LJ. British Society of Gastroenterology guidelines for the diagnosis of Barrett's oesophagus: are we casting the net too wide? Gut 2006;55:1821–1822.
32. Takubo K, Arai T, Sawabe M, et al. Structures of the normal esophagus and Barrett’s esophagus. Esophagus 2003;1:37–47.
34. Kusano C, Singh R, Lee YY, et al. Global variations in diagnostic guidelines for Barrett's esophagus. Dig Endosc 2022. doi:
10.1111/den.14342. [Epub ahead of print].
35. Connor MJ, Sharma P. Chromoendoscopy and magnification endoscopy in Barrett's esophagus. Gastrointest Endosc Clin N Am 2003;13:269–277.
37. Haringsma J, Tytgat GN, Yano H, et al. Autofluorescence endoscopy: feasibility of detection of GI neoplasms unapparent to white light endoscopy with an evolving technology. Gastrointest Endosc 2001;53:642–650.
38. Curvers W, Baak L, Kiesslich R, et al. Chromoendoscopy and narrow-band imaging compared with high-resolution magnification endoscopy in Barrett's esophagus. Gastroenterology 2008;134:670–679.
40. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006;131:1392–1399.
42. Abela JE, Going JJ, Mackenzie JF, McKernan M, O'Mahoney S, Stuart RC. Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy. Am J Gastroenterol 2008;103:850–855.
43. Levine DS, Blount PL, Rudolph RE, Reid BJ. Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus. Am J Gastroenterol 2000;95:1152–1157.
44. Kariv R, Plesec TP, Goldblum JR, et al. The Seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. Clin Gastroenterol Hepatol 2009;7:653–658.
45. Peters FP, Curvers WL, Rosmolen WD, et al. Surveillance history of endoscopically treated patients with early Barrett's neoplasia: nonadherence to the Seattle biopsy protocol leads to sampling error. Dis Esophagus 2008;21:475–479.
46. Chedgy F, Fogg C, Kandiah K, et al. Acetic acid-guided biopsies in Barrett's surveillance for neoplasia detection versus non-targeted biopsies (Seattle protocol): a feasibility study for a randomized tandem endoscopy trial. The ABBA study. Endosc Int Open 2018;6:E43–E50.
47. Kim KH, Lee JH, Jung HW, et al. Diagnosis and treatment of Barrett’s esophagus: opinions of Korean doctors. Kor J Neurogastroenterol Motil 2009;15:23–30.
48. Kim JH, Rhee PL, Lee JH, et al. Prevalence and risk factors of Barrett's esophagus in Korea. J Gastroenterol Hepatol 2007;22:908–912.
49. Kang SA, Kim DY, Kim JH, et al. A case of endoscopic mucosal resection for esophageal adenocarcinoma arising from Barrett's esophagus. Korean J Gastrointest Endosc 2005;31:237–242.
50. Kang J, An SG, Kim PJ, et al. Case reports : a case of esophageal adenocarcinoma arising from a short segment of Barrett's esophagus. J Neurogastroenterol Motil 2007;13:68–71.
51. Jung YK, Park JJ, Kim JH, et al. Two cases of adenocarcinoma arising from short segment Barrett's esophagus. Korean J Gastrointest Endosc 2004;28:18–24.
52. Choi CS, Seo GS, Kim YS, et al. A case of esophageal adenocarcinoma associated with Barrett's esophagus. Kor J Neurogastroenterol Motil 2006;12:81–86.
53. Fléjou JF. Barrett's oesophagus: from metaplasia to dysplasia and cancer. Gut 2005;54 Suppl 1(Suppl 1): i6–i12.
54. Ormsby AH, Goldblum JR, Rice TW, et al. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. Hum Pathol 1999;30:288–294.
56. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014;63:7–42.
57. Wani S, Rubenstein JH, Vieth M, Bergman J. Diagnosis and management of low-grade dysplasia in Barrett's esophagus: expert review from the clinical practice updates committee of the American Gastroenterological Association. Gastroenterology 2016;151:822–835.
60. Yao H, Wang L, Li H, et al. Proton pump inhibitors may reduce the risk of high-grade dysplasia and/or esophageal adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis. Expert Rev Clin Pharmacol 2022;15:79–88.
62. Seo KI, Park MI, Park SJ, Moon W, Kim SE, Han YJ. Effect of 15 minutes brief education for medical personnel in diagnosing Barrett’s esophagus. Korean J Helicobacter Up Gastrointest Res 2016;16:26–30.